CLDX
Celldex Therapeutics Inc
NASDAQ: CLDX · HEALTHCARE · BIOTECHNOLOGY
$32.14
-3.28% today
Updated 2026-04-29
Market cap
$2.52B
P/E ratio
—
P/S ratio
1,632.24x
EPS (TTM)
$-3.90
Dividend yield
—
52W range
$18 – $36
Volume
1.1M
Celldex Therapeutics Inc (CLDX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-72,027.00%
ROE
-40.60%
ROA
-26.10%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $4.93M | $-20.37M | 100.00% | -453.60% | -413.17% |
| 2007 | $5.10M | $-21.64M | 100.00% | -447.88% | -424.05% |
| 2008 | $7.46M | $-47.50M | 100.00% | -456.04% | -637.12% |
| 2009 | $15.18M | $-36.52M | 44.68% | -216.43% | -240.61% |
| 2010 | $46.79M | $-2.53M | 74.19% | -13.79% | -5.41% |
| 2011 | $9.27M | $-44.80M | 1.58% | -468.42% | -483.53% |
| 2012 | $11.20M | $-59.12M | 3.81% | -518.45% | -527.79% |
| 2013 | $4.11M | $-81.55M | 43.23% | -1,981.08% | -1,983.70% |
| 2014 | $3.59M | $-118.08M | 5.16% | -3,414.11% | -3,292.81% |
| 2015 | $5.48M | $-127.20M | 26.81% | -2,363.89% | -2,321.11% |
| 2016 | $6.79M | $-128.53M | -1,403.48% | -1,958.68% | -1,894.05% |
| 2017 | $12.74M | $-93.03M | -654.70% | -953.68% | -730.06% |
| 2018 | $9.54M | $-151.18M | -596.68% | -1,640.13% | -1,585.07% |
| 2019 | $3.57M | $-50.88M | -1,094.29% | -1,540.19% | -1,423.96% |
| 2020 | $7.42M | $-59.78M | -473.39% | -854.06% | -805.88% |
| 2021 | $4.65M | $-70.51M | -1,046.23% | -1,531.78% | -1,516.04% |
| 2022 | $2.36M | $-112.33M | -3,389.94% | -4,889.01% | -4,765.59% |
| 2023 | $6.88M | $-141.43M | -1,614.53% | -2,245.27% | -2,054.76% |
| 2024 | $7.02M | $-157.86M | -2,229.77% | -2,778.89% | -2,248.76% |
| 2025 | $1.50M | $-258.80M | 100.00% | -19,160.00% | -17,253.33% |